Sanofi has finalized its acquisition of Dynavax Technologies Corporation, a move that brings Dynavax’s adult hepatitis B vaccine HEPLISAV-B and other vaccine candidates into Sanofi’s portfolio. HEPLISAV-B is currently available in the United States and is distinguished by its two-dose regimen over one month. The acquisition also includes Dynavax’s shingles vaccine candidate, Z-1018, which is in phase 1/2 studies, as well as additional projects in the vaccine pipeline.
According to Sanofi, this acquisition will strengthen its position in adult immunization by combining Dynavax’s vaccines with Sanofi’s commercial resources and global development capabilities.
The tender offer for all outstanding shares of Dynavax common stock expired shortly after midnight on February 9, 2026. All conditions for the offer were met, and Sanofi accepted and will pay for all validly tendered shares. The transaction was completed through a merger of a wholly owned subsidiary of Sanofi with Dynavax under Delaware law. As a result, Dynavax is now an indirect wholly owned subsidiary of Sanofi. Shareholders who did not tender their shares will receive $15.50 per share in cash, without interest but subject to applicable taxes—the same amount offered during the tender process. As of February 10, 2026, Dynavax common stock will no longer be traded on the NASDAQ Global Select Stock Market.
Sanofi describes itself as an R&D-driven biopharma company focused on improving lives through medicines and vaccines based on its understanding of the immune system. The company states: “We chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.”
Sanofi has cautioned investors that forward-looking statements regarding future performance are subject to risks and uncertainties that could cause actual results to differ from expectations. These include regulatory actions or delays, integration challenges following acquisitions, competition from generic products or alternative therapies, research and development uncertainties, market conditions, exchange rate fluctuations, litigation risks related to intellectual property, cost containment measures, and broader economic factors.
The company advises that further information about these risks can be found in its filings with US Securities and Exchange Commission (SEC) and France’s Autorité des marchés financiers.
